Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,162 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,162 shares of the firm’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total transaction of $495,407.08. Following the transaction, the insider owned 104,742 shares in the company, valued at $44,655,704.28. This represents a 1.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, October 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $406.00, for a total value of $410,060.00.
• On Thursday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $414.22, for a total value of $1,242,660.00.
• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The stock was sold at an average price of $326.89, for a total value of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $320.73, for a total value of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The shares were sold at an average price of $265.58, for a total value of $905,627.80.

Natera Stock Performance

Shares of NTRA stock opened at $436.00 on Friday. Natera, Inc. has a 1 year low of $181.00 and a 1 year high of $437.41. The business’s fifty day moving average is $375.27 and its 200-day moving average is $265.54. The stock has a market cap of $62.85 billion, a PE ratio of -320.59 and a beta of 1.50.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The company’s revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.74) earnings per share. Equities research analysts predict that Natera, Inc. will post -1.14 earnings per share for the current year.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NTRA. BlackRock Inc. acquired a new stake in shares of Natera during the 2nd quarter valued at $2,962,770,000. Bank of America Corp DE purchased a new position in shares of Natera during the 2nd quarter valued at $199,960,000. Legal & General Group Plc acquired a new position in shares of Natera in the second quarter worth $150,143,000. Bank of New York Mellon Corp acquired a new position in shares of Natera in the second quarter worth $149,278,000. Finally, Avala Global LP acquired a new position in shares of Natera in the second quarter worth $124,867,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

NTRA has been the topic of several research reports. Stephens upped their price target on Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Piper Sandler raised their price objective on Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. JPMorgan Chase & Co. lifted their target price on Natera from $360.00 to $460.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. Robert W. Baird set a $348.00 target price on Natera in a report on Friday, August 7th. Finally, Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $394.31.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.